Viatris Readies Landmark Botox Biosimilar, Clinical Trial Coming In H1 2024
Key IND Filing With USFDA Planned For Year-End; Launch In 2026 Slated
Viatris has provided the latest on plans to bring a biosimilar to the world-renowned Botox cosmetic and therapeutic brand, while also discussing other opportunities on the slate, including its pipeline of complex injectables.
